Humacyte (HUMA) Cash from Financing Activities (2020 - 2026)
Humacyte (HUMA) reported Cash from Financing Activities of $23.3 million for Q1 2026, down 50.1% year-over-year from $46.7 million in Q1 2025, and down 59.21% quarter-over-quarter from $57.2 million in Q4 2025.
Humacyte (HUMA) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has 7 years of Cash from Financing Activities data on file, last reported at $23.3 million in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $23.3 million, down 50.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $38.1 million (down 61.21% YoY), and the FY2025 annual result was $61.5 million, down 46.15% from the prior year.
- Cash from Financing Activities slipped to $23.3 million in Q1 2026 per HUMA's latest filing, from $57.2 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $62.8 million in Q1 2024 and troughed at -$44.6 million in Q3 2025.
- A 5-year average of $11.9 million and a median of -$212000.0 in 2022 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities soared 15453.3% in 2024, then tumbled 5352.18% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at -$212000.0 in 2022, then slumped by 58.02% to -$335000.0 in 2023, then jumped by 15325.67% to $51.0 million in 2024, then increased by 12.09% to $57.2 million in 2025, then sank by 59.21% to $23.3 million in 2026.
- Business Quant data shows HUMA's Cash from Financing Activities at $23.3 million in Q1 2026, $57.2 million in Q4 2025, and -$44.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 85,464.43 |
| 10 | Humacyte | 267.09 Mn | 218.55 Mn | -1.54 Mn | 23.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.32 Mn |
| Mar 31, 2026 | 23.32 Mn |
| Dec 31, 2025 | 57.17 Mn |
| Dec 31, 2025 | 57.17 Mn |
| Sep 30, 2025 | -44.59 Mn |
| Sep 30, 2025 | -44.59 Mn |
| Jun 30, 2025 | 2.17 Mn |
| Jun 30, 2025 | 2.17 Mn |
| Mar 31, 2025 | 46.74 Mn |
| Mar 31, 2025 | 46.74 Mn |
| Dec 31, 2024 | 51.01 Mn |
| Dec 31, 2024 | 51.01 Mn |
| Sep 30, 2024 | 849,000.00 |
| Sep 30, 2024 | 849,000.00 |
| Jun 30, 2024 | -467,000.00 |
| Jun 30, 2024 | -467,000.00 |
| Mar 31, 2024 | 62.80 Mn |
| Mar 31, 2024 | 62.80 Mn |
| Dec 31, 2023 | -335,000.00 |
| Dec 31, 2023 | -335,000.00 |